跳至主要内容
临床试验/NCT06364397
NCT06364397招募中不适用

Efficacy of ERCP in the Diagnosis and Treatment of Idiopathic Recurrent Acute Pancreatitis: a Randomized Controlled Trial

Changhai Hospital1 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2024年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
158
试验地点
1
主要终点
Recurrence rate of AP

研究概览

简要总结

The goal of this clinical trial is to learn if endoscopic retrograde cholangiopancreatography (ERCP) works to treat idiopathic recurrent pancreatitis (IRAP) in adults. It also clarify the efficacy of ERCP in the diagnosis of IRAP. The main questions it aims to answer are:

Does ERCP reduce the frequency of pancreatitis episodes in IRAP patients? Does ERCP contribute to identify the etiology of IRAP patients?

Participants will be randomly allocated to receive ERCP (pancreatic sphincterotomy and pancreatic stent placement) or conservative treatment and be followed for 1 year.

详细描述

Recurrent acute pancreatitis (RAP) is defined as 2 or more distinct episodes of acute pancreatitis (AP) with complete resolution between each episode, and absence of irreversible structural and functional changes in pancreas. RAP has an estimated annual incidence of 8-10 per 100,000 and the recurrence rate is as high as 10-30% in AP patients. At present, biliary, alcoholic and hypertriglyceridemia are common causes of RAP. There are also a variety of causes that may contribute to recurrent episodes of AP, such as gene mutations, pancreas divisum, ampullary neoplasms and sphincter of Oddi dysfunction. About 80% of RAP patients can be identified through routine clinical investigations (include proper history, physical examination, imaging examination); however, the etiology in up to 20% of cases still not be clarified and these patients is called idiopathic recurrent acute pancreatitis (IRAP).

Endoscopic retrograde cholangiopancreatography (ERCP) is an important minimally invasive treatment for pancreatic diseases. However, the role of ERCP in IRAP patients with normal biliary and pancreatic anatomy remains controversial and there is a lack of high-quality clinical research evidence on endoscopic treatment of IRAP. In a small sample size (N=34) open-label randomized controlled study, IRAP patients were assigned to the experimental group with pancreatic duct stent placement and the control group with selective pancreatograms but no stent. This study demonstrated that stent placement was able to reduce the recurrence rate of AP (53% vs 11%, P < 0.02). Coté et al performed an open-label randomized trial (N=89) of ERCP with sphincter of Oddi manometry for IRAP patients. Among patients with pancreatic sphincter dysfunction, they found that biliary sphincterotomy and combination of biliary and pancreatic sphincterotomy have similar effects in preventing recurrence of AP, and there was also no significant difference between biliary sphincterotomy and sham surgery in patients with normal sphincter of Oddi manometry. However, some retrospective studies had shown that sphincterotomy works to reduce the recurrence rate of acute pancreatitis.

Currently, there is a shortage of high-quality evidence, and the wide variation in different study designs has led to controversial conclusions. Given the long-standing controversy, we propose to conduct a randomized controlled trial to investigate the efficacy of ERCP in the diagnosis and treatment of Idiopathic recurrent acute pancreatitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Aged 18 to 70 years.
  • •Patients diagnosed with IRAP:
  • •Previously experienced 2 or more distinct episodes of acute pancreatitis (AP) with complete resolution between each episode, and absence of irreversible structural and functional changes in pancreas. The diagnosis of AP is based on the Atlanta criteria and is documented in the medical record.
  • •The etiology of RAP remains undetermined after routine clinical investigations, including history, laboratory examination, imaging examination (CT, MRI/MRCP, EUS). Patients who still have AP episodes after elimination of the etiology also be included.
  • •At least 1 episode of AP one year prior to enrollment.
  • •Consent to participate in the study and sign the informed consent form.

排除标准

  • •Prior sphincter intervention.
  • •Not recovered from prior AP attack.
  • •Prior pancreatic surgery.
  • •Contraindications to ERCP.
  • •Major mental illness or serious health problems that are not suitable for participation in the study.
  • •Pregnancy or plan for pregnancy within 12 months of enrollment.
  • •Other conditions that inappropriate to participant in the study.

研究组 & 干预措施

ERCP group

Experimental

Participants will undergo ERCP. Indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place. Participants will accept health education and conservative management of clinical routines. Follow-up visits for participants occurred at 3, 6, 9 and 12 months after enrollment.

干预措施: ERCP (Procedure)

ERCP group

Experimental

Participants will undergo ERCP. Indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place. Participants will accept health education and conservative management of clinical routines. Follow-up visits for participants occurred at 3, 6, 9 and 12 months after enrollment.

干预措施: Health education and conservative management of clinical routines (Combination Product)

conservative treatment group

Active Comparator

Participants will be given health education and conservative management of clinical routines. Follow-up visits for participants occurred at 3, 6, 9 and 12 months after enrollment.

干预措施: Health education and conservative management of clinical routines (Combination Product)

结局指标

主要结局

Recurrence rate of AP

时间窗: 1 year after enrollment

Proportion of patients with at least one episode of AP 1 year after enrollment (AP within 1 month of the index ERCP was excluded).

次要结局

  • Ratio of reduced AP episodes(1 year after enrollment)
  • Severity of AP(1 year after enrollment)
  • Proportion of patients diagnosed by ERCP.(1 year after enrollment)
  • Proportion of patients with reduced AP episodes(1 year after enrollment)
  • Evaluation of quality of life(1 year after enrollment)
  • Evaluation of psychological condition(1 year after enrollment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhaoshen Li

Professor

Changhai Hospital

研究点 (1)

Loading locations...

相似试验

已完成
不适用
Left Lateral Position and Prone Position for Endoscopic Retrograde CholangiopancreatographyCholedocholithiasis
NCT02594475Chuncheon Sacred Heart Hospital64
尚未招募
不适用
PROceeding With Advanced Techniques in Case of Distal Malignant Biliary Obstruction and Difficult Biliary Cannulation comparEd With Therapeutic-EUS: the PROMETHEUS TrialMalignant Biliary Obstruction
NCT06550973Istituto Clinico Humanitas220
Unknown
不适用
Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal DisordersPediatric GastroenterologyBile LeakBiliary and Pancreatic StonesCholangiocarcinomaCholangitisRecurrent PancreatitisGastric MalignanciesPancreatic DivisumGallstonesBile Duct CancerAmpullary CancerDuodenal CancerBarrett's EsophagusAcute and Chronic PancreatitisBiliary StricturesCholedocholithiasisBile Duct DisordersObstructive JaundicePancreatic Disorders (Noncancerous)Pancreatic PseudocystsColorectal CancerPancreatic CancerEsophageal Cancer
NCT01438385Weill Medical College of Cornell University12,000
尚未招募
不适用
Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde CholangiopancreatographyCholedocholithiasisCholedocholithiasis With Acute CholangitisSclerosing CholangitisPancreatic Cancer ResectablePancreatic Cancer Non-resectableCholangiocarcinomaBiliary Fistula
NCT06670547Germans Trias i Pujol Hospital3,000
已完成
不适用
Infection Control in ERCP Using a Duodenoscope With a Disposable CapBile Duct Diseases
NCT04040504University of Calgary520